Triple-negative vimentin-positive heterogeneous feline mammary carcinomas as a potential comparative model for breast cancer

Diego Caliari¹*, Valentina Zappulli¹†, Roberta Rasotto², Barbara Cardazzo¹, Federica Frassineti¹, Michael H Goldschmidt³ and Massimo Castagnaro¹

Abstract

Background: Human breast cancer is a heterogeneous disease classified by molecular subtyping into luminal A, luminal B, HER2-overexpressing, basal-like, claudin-low and normal-breast like. The routinely applied and standardized immunohistochemical-based surrogates of this classification group together the last three entities as triple-negative breast cancer (TNBCs) that show the most diverse and complex heterogeneity and represent a therapeutic challenge.

In the present work 156 feline mammary lesions consisting of feline mammary carcinomas (FMCs), benign neoplasms, and hyperplastic/dysplastic tissues were evaluated histologically and by immunohistochemistry for expression of basal and luminal cytokeratins (CK), vimentin, alpha-smooth muscle actin, calponin, estrogen receptor (ER) alpha (α), and progesterone receptor (PR). Thirty-seven FMCs with 27 matched non-neoplastic controls were also investigated for gene expression of ERα, ERβ, PR, and HER2.

Results: A large group of hormone receptors (HRs)-negative aggressive carcinomas - that did not overexpress HER2 - could be distinguished from the less aggressive (10.8%) and benign (8%) HRs + tumors, that showed bilineage (luminal and myoepithelial) differentiation. Immunohistochemical evaluations of cytoplasmic filaments indicated that HRs- FMCs are vimentin+, CK14+, and CK5_6+ carcinomas that may resemble the TNBCs (basal like/claudin low) described in women. The identification of luminal and myoepithelial progenitors within the mammary ductal system suggested potential cells/sites of origin of these tumors. A diffuse and never previously described CKs/vimentin luminal cell co-expression was detected in the non-neoplastic ducts, indicating a potential bilineage progenitor.

Conclusions: These results indicate and potentially explain the high incidence of triple-negative, vimentin + aggressive tumors in cats that may be used to elucidate some of the challenging features of TNBCs in women.

Keywords: Mammary tumor, Feline, Human breast cancer, Vimentin, Markers, Triple-negative
are frequently high-grade aggressive invasive ductal carcinomas, lack a specific targeted therapy, and are a heterogeneous group of breast tumors [10]. Approximately 70-75% of TNBCs share similarities with the basal-like breast cancer (BLBC) molecular subtype; therefore they have been considered erroneously as synonyms [9]. Histologically, the majority of TNBCs are invasive ductal carcinomas but medullary, metaplastic, and adenosquamous histological subtypes share the triple negativity despite a more favorable prognosis [11]. Using transcriptome analysis distinct classes of TNBCs have been recognized: the BLBCs, the normal breast-like HBCs, and the newly identified claudin-low subtype [12,13], but further efforts described even more distinct TNBCs signatures [10]. At present, there is no standardization of IHC markers able to identify the TNBCs classes. BLBCs show expression of basal cytokeratins (CK5/6 and/or CK17 and/or CK14), epidermal growth factor receptor (EGFR), C-kit (CD117), and a high frequency (80%) of p53 mutation [12]. In contrast, claudin-low tumors show epithelial-mesenchymal transition (EMT) features, immune system responses, and stem cell-associated biological markers [13]. Many researchers have speculated that the genetically defined HBC subtypes may represent transformation of stem cells with arrest at specific stages of development or, alternatively, direct transformation of various mature cell types [3,5,14]. Data suggest that invasive HBCs may be placed on a normal mammary differentiation hierarchy and in this hypothetical view of developmental origin the claudin-low class would be considered as the most primitive subtype [3].

In the feline species, mammary cancer is a leading cause of death and the most common tumor in female cats (queens). Feline mammary tumors (FMTs) are frequently high-grade invasive carcinomas (80-90%) that lack a well-differentiated tumor-suppressor myoepithelial component which is much more common in canine mammary tumors [15,16]. Although there are no robust and standardized results for hormone receptors (HRs) and HER2 positivity, feline mammary carcinomas (FMCs) often lack significant levels of ERa and PR [17-23]. In addition, FMCs have been associated with decreased expression of adhesion molecules [24] and high expression of basal cytokeratins and vimentin [25], and a “basal-like” subtype was identified by IHC-analyses [17].

Further demonstration of these interesting similarities between FMCs and TNBCs might offer relevant information in veterinary medicine and might support FMC as a useful spontaneous model for pathogenetic mechanisms and therapeutic approaches [17,18,26], overcoming some of the limitations of HBC cell-line based studies and mouse modeling [27-30].

The aim of this study was to determine the immunohistochemical and molecular features of non-neoplastic mammary gland tissue and FMTs in term of HRs, HER2, and cytoplasmic filaments expression and to provide additional information on the possible origin of HRs-vimentin + FMTs that may be useful for further analyses of HBC.

Methods

Samples collection and follow-up data

The present IHC and molecular study was conducted on a population of 81 queens with mammary gland lesions. For IHC analysis paraffin-embedded samples, submitted to the Diagnostic Service of Veterinary Anatomical Pathology (University of Padua, Italy) routinely collected during surgery and processed as previously described [22], were used. Distant metastases were not reported at the time of diagnosis. In addition, for 37/81 cases a portion (approx. 4 × 4 × 6 mm) of enlarged mammary tissue was collected at the time of surgery and was stored in RNA Later (Ambion, Austin, TX) (−80°C). Twenty-seven samples of adjacent presumed normal mammary parenchyma (matched controls) were also collected immediately after surgery as the adjacent portion of the presumptive tumor with no further sampling for the subject and identically stored.

Data on the one-year post-surgical survival and the development of local relapses and distant metastases were available for 43 subjects. Twenty-two of 40 cats (55%) with malignant tumors were dead within the first year after surgery; 12/40 (30%) of the cats had visceral metastases and 17/40 (42.5%) had local recurrences.

Histopathology

Histological evaluation of the paraffin-embedded samples from the 81 subjects was performed by two or more ECVP-certified pathologists. Morphological diagnoses were based on the WHO classification [15] and on the recent literature [16,31] that describes new mammary tumor subtypes that includes the new categories of comedocarcinoma, ductal adenoma/carcinoma, and intraductal papillary adenoma/carcinoma. The ductal and intraductal papillary (“ductal-associated”) tumors were confirmed by IHC as biphasic (see later). Criteria of malignancy were: significant nuclear/cellular pleomorphism, presence of random areas of necrosis, and mitotic index (MI). The MI was calculated as the total number of mitoses per 10 high power fields (40×, Olympus BX40) in the areas with the highest proliferative activity. A MI > 3 was used as cut-off for malignancy in borderline (benign vs malignant) lesions. Grading of malignant tumors was performed using the modified Elston and Ellis [32] system [33]. Peritumoral lymphatic invasion was also assessed. Before RNA extraction half of the RNA Later-preserved sample was embedded in paraffin for histological evaluation.
**IHC analysis**

Four-micron-thick sections were cut, mounted on Superfrost®Plus microscope slides (Menzel GmbH, Braunschweig, Germany) and dried at 37°C for 30 minutes. IHC evaluations for cytokeratins (CK) CK5-6, CK14, CK8-18, panCK, calponin (CALP), vimentin (VIM), alpha-smooth muscle actin (aSMA), ERα, and PR were performed using an automated immunostainer (BenchMark XT®, Ventana Medical System Inc., Tucson, AZ). See Table 1 for specific primary antibodies and protocols. The incubation temperature for all the antibodies was 40°C and the ultraView Universal DAB detection Kit was applied (Ventana Medical System Inc., Tucson, AZ).

Internal positive controls were the epidermis, adnexal epithelium, the non-neoplastic mammary glands (panCK, CK5_6, CK14, CK8_18), and vessels wall (CALP and aSMA). Sections of feline uterus were used as positive controls for ERα and PR.

For all markers positivity was evaluated as the percentage of positive neoplastic cells counted in at least 10 random high-power fields (40×), avoiding necrotic areas and the immediately adjacent portions, for a total of 1,000 cells. Specifically, nuclear positivity was evaluated for ERα and PR, and samples were considered positive if >1% cells were stained, whereas cytoplasmic brown staining was considered as positive for CK5_6, CK14, CK8_18, panCK, CALP, VIM, and aSMA. For the latter markers the morphology and location of positive cells was determined, and a positive sample cut-off was not established.

Light microscopic evaluation of each marker was conducted in a blinded manner. Consensus was achieved with a third pathologist in discordant cases. Positivity was evaluated separately for all types of lesions (malignant, benign, hyperplastic) and the normal mammary tissue.

**RNA extraction and sequencing**

Samples preserved in RNA Later (approx. half of the sample) including 37 tumoral and 27 normal glands, homogenized in Trizol Reagent (Invitrogen, Carlsbad CA) and total RNA isolation was completed following the manufacturer’s protocol. The extracted RNAs were treated with RQ1 RNase-free DNase (Promega, Madison, WI) and purified with a standard phenol–chloroform extraction.

One microgram of total RNA from each sample was reverse transcribed using a reverse transcriptase (Supercript II, Life technologies Grand Island, NY) and random hexamers to obtain first-strand cDNA. The cDNA was then used as a template for quantitative real-time PCR to evaluate the relative expression of ERα, ER beta (β), PR, Erb-B2 genes in feline mammary lesions and

### Table 1 Antibodies and details of the protocols applied for the immunohistochemical examination

| Markers             | Antibodies (mouse anti-human) clone and producer | Dilution* | Unmasking | Incubation time** |
|---------------------|--------------------------------------------------|-----------|-----------|-------------------|
| Cytokeratin 5/6     | Clone D5/16 B4 Dakocytomation                     | 1:100     | CCR       | 24 min            |
|                     |                                                  |           | + protease 2 min |                   |
| Cytokeratin 14      | NCL-L-LL002 Novocastra                           | 1:20      | CCR       | 18 min            |
| Cytokeratin 8/18    | NCL-L-SD3 Dakocytomation                         | 1:20      | protease 8 min | 24 min            |
| Pancytokeratin      | Clone AE1/AE3 Dakocytomation                     | 1:100     | CCR       | 16 min            |
| Calponin            | Clone Calp Dakocytomation                        | 1:200     | CCR       | 12 min            |
| Vimentin            | Clone V9 Dakocytomation                          | 1:100     | CCR       | 18 min            |
| α-smooth muscle actin| Clone 1A4 Dakocytomation                        | 1:100     | no        | 10 min            |
| Estrogen receptor   | NCL-ER-6 F11 Novocastra                          | 1:40      | CCS       | 14 min            |
| Progesteron receptor| Clone: PR10A9 Immunotech                         | 1:100     | CCE       | 18 min            |

CCR, cell conditioning reduced: 30 minutes at 95°C; CCS, cell conditioning standard: 60 minutes at 95°C; CCE, cell conditioning extended: 90 minutes at 95°C.

*The primary antibody was diluted in the Antibody Diluent (Ventana Medical System Inc., Tucson, AZ).

**Incubation time for primary antibody; min, minutes.
matched controls. The real-time PCR MGB assay were designed using the Assay-by-design service (Life Technologies, Grand Island, NY) based on the coding sequences of the feline Erα, Erβ, Pr, Erβ-B2 as target genes and b-Glucuronidase (b-Glu) as the reference gene (Acc. Num. AY605260, HE608843, JX965384, AY702651, AF012423). An aliquot (2.5 μl) of diluted (1:50) cDNA template was amplified in a final volume of 10 μl, containing 5 μl of TaqMan® Universal PCR Master Mix (Life technologies Grand Island, NY). The amplification protocol consisted of an initial step of 2 min at 50°C and 10 min at 95°C, followed by 45 cycles of 10 s at 95°C and 30 s at 60°C. All experiments were carried out in a ABI PRISM 7000 (Life technologies Grand Island, NY). For each sample, the Ct (Cycle threshold) was used to determine the relative amount of target gene; each measurement was made in triplicate, and normalized to the reference gene b-Glu, which was also measured in triplicate.

A target gene fold-change (FC) value was finally calculated for each sample using the ΔΔCp method (ΔCpTarget-reference sample - ΔCpTarget-reference calibrator) using cat ovarian cDNA as calibrator.

Statistical analysis
Statistical analysis of IHC and molecular expression profiles and correlation with histological parameters and follow-up data were performed with the SPSS advanced statistical package 13.0 (SPSS Inc., Chicago, Illinois). The Spearman correlation test, the Kruskal-Wallis test, the Mann Whitney test, the Wilcoxon test, the Wilcoxon signed ranks test were performed. Of the hyperplastic/dysplastic tissues 28 cases were ERα-/PR-; only one specimen had normal non-hyperplastic associated mammary tissue that was also ERα-/PR-. Twenty-five out of twenty-eight cases were adjacent to HRs-negative tumors and 3/28 cases were not associated with a tumor. There was no association between HRs-status and ovariectomy.

Both in normal and hyperplastic/dysplastic tissues CK8_18 was diffusely expressed in luminal cells (with the exception of the single case of epitheliosis) (Figure 1a). In all cases, VIM was co-expressed with CK8_18 in the luminal compartment of both interlobular and intralobular ducts (Figure 1a,b). In the hyperplastic lobules CK14 was observed in luminal cells exclusively in the terminal portion of the intralobular ducts (Figure 1c). CALP, aSMA, and VIM diffusely stained basal (myoepithelial) cells from the ducts to the lobules, whereas CK14 and CK5_6 were evident at the same basal location, but only in the interlobular and intralobular ducts (Figure 1c,d).

IHC evaluations
All 156 lesions and the normal tissues showed 100% positive staining to panCK of the epithelial cells (except one metastasis with 37% panCK + cells). CALP and aSMA were never detected in the luminal epithelial cells. The other IHC results are summarized in Table 2.
Table 2 Expression of markers in luminal neoplastic cells examined by immunohistochemistry

| No. | Grading | PR | ERα | CK8_18 | VIM | CK5_6 | CK14 |
|-----|---------|----|-----|--------|-----|-------|------|
|     |         |    |     | Percentages of + luminal epithelial cells: Mean ± SD (number of positive samples, range of positive cells) |     |       |      |
| Normal glands | 8 | 24 ± 24.60 (5, 25–72) | 38 ± 29 (6, 22–70) | 100 ± 0 (8) | 100 ± 0 (8) (ductal) | - | 100 ± 0 (8) (terminal intralobular ducts) |
| Hyperplasia/dysplasia | 73 | 5.59 ± 17 (13, 2.10–87) | 10.58 ± 25.54 (25, 1.30–100) | 100 ± 0 (73) | 100 ± 0 (72)a (ductal) | - | 100 ± 0 (29)a (terminal intralobular ducts) |
| Benign tumors | 6 | 15.55 ± 17.47 (3, 27–38) | 26.97 ± 38.23 (4, 6–100) | 100 ± 0 (6) | 42.58 ± 36.62 (5, 7.5–100) | - | - |
| Malignant tumors | 68 | 1.54 ± 9.18 (3, 4.80–70) | 2.85 ± 13.86 (6, 2–87.3) | 83.45 ± 30.22 (65, 2–100) | 53.19 ± 34.73 (62, 0.5–100) | 7.76 ± 17.83 (29, 0.5–100) | 32.05 ± 32.96 (62, 0.5–100) |
| DC/IPC | 8 | I | (1, 4.80%)b | 12.38 ± 25.42 (4, 2–73) | 100 ± 0 (8) | 27.31 ± 28.48 (5, 17.8–80) | - | (1, 34%)f |
| Other subtypes | 12 | I | (1, 70%)b | (1, 7%)b | 72.67 ± 32.35 (11, 33–100) | 51.41 ± 37.74 (11, 1.2–100) | 5.69 ± 16.63 (6, 5–36) | 32.10 ± 36.62 (9, 0.5–100) |
| | 22 | II | - | - | 87.18 ± 25.39 (22, 5–100) | 57.85 ± 36.88 (21, 7–98) | 6.98 ± 10.06 (5, 0.5–28) | 37.91 ± 29.96 (22, 0.5–100) |
| | 26 | III | (1, 29.70%)b | (1, 87.30%)b | 78.96 ± 35.79 (24, 2–100) | 58.04 ± 34.80 (25, 3.3–100) | 12.37 ± 25.39 (17, 0.5–100) | 35.49 ± 33.84 (23, 0.5–100) |
| LN Metastases | 9 | - | - | - | 81.33 ± 35.62 (9, 2–100) | 50.83 ± 42.42 (9, 0.5–98) | 5.33 ± 12.16 (3, 0.5–32.7) | 28.47 ± 35.47 (9, 0.5–97) |

SD, standard deviation; ER, estrogen receptor; PR, progesterone receptor; DC, ductal carcinoma; IDPC, intraductal papillary carcinoma; LN, lymph node; a One case of DC; b One different case of tubulopapillary carcinoma each; c One negative case of epitheliosis; d Exclusively intralobular ducts in hyperplastic lobules were positive; e One case of DC.
Five out of the six (83%) benign FMTs were positive to HRs (2 ERα+/PR+; 2 ERα+/PR−; 1 ERα+/PR+) (Figure 2e). The ERα−/PR− intraductal papillary adenoma had adjacent non-neoplastic tissue that was also ERα−/PR− and 100% of the luminal neoplastic cells were VIM+ in this case. VIM was totally found in 5/6 benign tumors in 42.6% of luminal neoplastic cells, as average (range 7.5−100%) (Figure 2b).

In the FMCs significant differences were found between the “ductal-associated” carcinomas and the “non-ductal-associated” carcinomas. Five out of eight (62.5%) malignant “ductal-associated” tumors were either ERα+ (Figure 2f) or PR+ in the luminal compartment that showed neither CK5_6 nor CK14 IHC expression. Only one HR− ductal carcinoma showed luminal CK14 expression (34% cells). Luminal VIM was observed in 5/8 cases (62.5%), they were PR− and either ERα+ or ERα−. Similarly to benign tumors and non-neoplastic tissues they were all positive to CK 8_18 in the luminal cells.

In “non-ductal-associated” FMCs, only 4 cases (6%) were HR positive (7% ER+ + cells, 29.70% PR + cells, 70% PR + cells, 87.3% ER+ + cells, respectively). All these samples were negative for luminal expression of CK5_6. Luminal VIM was present in all (16%, 21%, 80%, and 98% + cells, respectively), and one case was CK14+ (19% luminal cells with 98% VIM+). They all showed 100% CK8_18+ neoplastic luminal cells. In the 94% of the ERα−/PR− FMCs a loss of CK8_18 was found (Figure 3a), whereas there was increased VIM, CK5_6, and CK14 expression (Figure 3b,c,d). 13/29 (45%) and 41/61 (67%) “non-ductal associated” FMCs showed >10% neoplastic CK5_6+ and CK14+ cells, respectively. VIM and CK5_6 expression increased progressively with the grade. The nine metastases showed a pattern of expression similar to ERα−/PR− FMCs for all the markers.

Statistical analyses showed that ERα and PR expression was significantly decreased in FMCs when compared to benign tumors, hyperplastic/dysplastic lesions, and normal tissue, and when compared to paired samples (P < 0.01). CK8/18 was the only other marker that showed a significant decrease in FMCs when compared to benign/non-neoplastic lesions. Positive correlations were found between ERα and both PR and CK8_18 (P < 0.01) and between CK14 and CK5_6 (P < 0.05). A negative correlation was identified between ERα expression and tumor grade (P < 0.01). No significant associations were found with survival and other histopathological parameters.

mRNA evaluations
In all the examined tissues ERα, ERβ, PR and HER2 were all expressed, despite large variances among samples (Table 3). The ERα and PR gene expression were significantly decreased (P < 0.0001 and P < 0.01, respectively) in FMCs compared to matched non-neoplastic mammary
tissue. ERβ and HER2 showed no significant difference between tumoral and non-tumoral matched samples. A positive correlation was found exclusively between ERα and PR gene expression both in FMTs (P < 0.001) and in non-neoplastic mammary glands (P < 0.05). Furthermore, ERα expression was negatively correlated with tumor grade (P < 0.05) while for PR the negative correlation was only close to significance (P = 0.06).

**Discussion**

In this study we present data on the phenotypic and prognostic markers expression in FMTs and associated normal/hyperplastic/dysplastic glands. We found two tumor subgroups: *i.* less aggressive biphasic HRs+ (“ductal-associated”) tumors and *ii.* more common and aggressive HRs- heterogeneous carcinomas. We compared proteins levels as detected by IHC with mRNA levels of HRs and we determined ERβ and HER2 expression by RT-PCR in matched samples. We demonstrated the distribution of cell subtypes – both luminal epithelial and basal/myoepithelial lineages – in non-neoplastic glands, and found an unusual and previously undocumented ductal luminal VIM positivity (co-expressed with CK8-18) and a luminal CK14 expression specifically located in the terminal intra-lobular ducts. Both CK14 and CK5_6 staining were increased in HRs- carcinomas.

In our study population (81 queens) the high ratio of malignant (93%) versus benign tumors, the frequency of invasive carcinomas of the tubular (28%) and tubulopapillary subtypes (19%), and the relative low frequency of ERα+ and/or PR + FMCs correspond with the published data [15,18,33].
In HBC the clinical and pathological classification of subtypes relies on ER, PR, HER2, and Ki-67 IHC labeling and this represents a convenient shorthand substitute, although not identical, to the molecular “intrinsic” subtypes [34,35]. Nevertheless, wide variability of the performance of these tests and inaccurate results (20%) are still detected [6,36,37].

In veterinary medicine, the application of internationally recognized guidelines has not yet been implemented generating an even more imprecise picture of HRs status in FMTs (<40% HRs + FMCs in most studies) [18,21,38]. When assessing the HRs expression by IHC in our feline samples, we detected 12% of normal and 38% of hyperplastic/dysplastic glandular samples that were ER-/PR-; these were always associated with HRs- tumors. Either a technical artifact or a loss of hormone stimulation should be considered as possible explanation for these results. However, data regarding time of samples fixation and age of ovariectomy, that might both affect HRs expression, were not available for our samples. Nevertheless, our data support the idea that aggressive FMCs tend to be HRs- (87%). Also, a progressive loss of HRs expression from non-neoplastic to neoplastic samples as well as from benign to malignant tumors was evidenced in accordance with the literature [18,21,38]. In addition, the subgroup of less aggressive grade I “ductal-associated” carcinomas, defined as ductal and intraductal papillary tumors by morphology and IHC [31], had an increased frequency of ERa positivity when compared to all other carcinomas. Furthermore, ERa and PR expression was positively correlated with CK8_18, a marker of well-differentiated luminal cells, and negatively correlated with tumor grade as previously described [18,21], again indicating of a loss of HRs in less differentiated and more aggressive tumors.

We associated gene expression analysis to the IHC evaluation of ERa and PR for a subset of samples. The significant reduction of ERa and PR proteins in FMCs

| Table 3 RT-PCR fold-change values of markers |
|--------------------------------------------|
| Feline mammary carcinomas (No. 37)        |
| HER2 | ERα | ERβ | PR    |
|------|-----|-----|-------|
| 1.56 | 0.12| 0.04| 0.03  |
| Median value |     |     |       |
| Variance | 5.12| 2.25| 0.01 | 0.34 |
| Range | 0.13-10.1 | 0.01-8.32 | 0-0.38 | 0-3.39 |
| Normal mammary glands (No. 27)            |
| HER2 | ERα | ERβ | PR    |
|------|-----|-----|-------|
| 2.16 | 1.63| 0.03| 0.31  |
| Median value |     |     |       |
| Variance | 7.68| 4.33| 0.01 | 3.10 |
| Range | 0.59-10.93 | 0.05-9.94 | 0-0.43 | 0-7.40 |

ERα, estrogen receptor alpha; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.
was confirmed in matched samples, allowing a correction for any subject-related variability.

In our work, we also studied ERb expression as already done in HBC [39]. Similarly to HBC, in our feline samples, the ERb gene resulted expressed at very low levels in all samples.

Data concerning HER2 status in FMTs are highly controversial with values ranging from 5.5% to 90% of positive tumors probably due to different protocols and evaluation methods [17,19,20,22,23,38,40]. In our work we evaluated HER2 by RT-PCR and we found no significant difference in HER-2 expression between FMCs and matched non-neoplastic tissues. A more than 2-FC increased was detected in 32% FMCs. Only one study analyzed the expression of HER2 mRNA in FMCs that was 3 to 18-FC increased in 6/11 tumors [19]. A previous work from our group analyzed the IHC expression of HER2, Ki-67, and p53 on the same FMTs samples used in this study [22]. When we tested HER2 expression by IHC and strictly applied the Food and Drug Administration (FDA)-approved HercepTest scoring system (DAKO, Glostrup, Denmark) [41], only a single carcinoma scored 3+ [22]. This carcinoma demonstrated the highest RT-PCR relative quantification of HER2 (single case with a 10-FC increase). Other authors tested HER2 IHC expression in FMTs, however variability of methods of assessment makes comparison non-robust [17,19,23,41]. Our data suggests that when strict criteria for HER2 assessment (3+) are used, there are a few cases of HER2-overexpressing FMTs.

On the basis of these and previous results [22] the majority of our FMTs samples had therefore a “triple-negative” phenotype (1/6 benign and 58/68 (85%) malignant).

In humans, there is no consensus on the stratification of TNBCs due to their complex heterogeneity [9,13]. IHC-based surrogates have been discussed to diagnose the TNBCs classes (BLBCs, claudin-low, and normal breast-like) [13].

In our “triple-negative” FMCs we evidenced the appearance of CK5_6 in the 42.6% of the carcinomas (7.8%, average of positive neoplastic cells) and CK14 in the 91% of the carcinomas (32%, average of positive neoplastic cells), comparable to previous findings [17,25], and possibly suggestive of a BLBC phenotype [17]. However, we were unable to demonstrate a significant p53 accumulation in the same dataset (13% of the FMCs) [22], which should be a characteristic of BLBCs in women [13].

A few studies have found decreased expression of adhesion molecules in FMTs [24,25] suggesting a possible EMT-based aggressive phenotype, which is reported for the claudin-low subclass [13]. In the present work, we found vimentin expression (91% of the FMCs) in the neoplastic cells (53% average) a feature also described in other studies [26,42,43]. Vimentin is considered a mesenchymal marker responsible for cell integrity and resistance against stress [44] and its expression in HBC has been addressed as a feature of the claudin-low phenotype [45-47]. However, its prognostic role in HBC in term of both survival and metastases development is not clear [45-48]. One study hypothesized that vimentin-positive invasive HBCs have a direct myoepithelial histogenesis, or a EMT phenotype, or may derive from breast progenitor cells with bilinear (luminal and myoepithelial) differentiation potential [45].

This information would support a significant similarity between the aggressive FMCs and the claudin-low TNBC class.

Our findings on the cell lineages phenotype and distribution in the non-neoplastic feline mammary gland (see a schematic summary in Figure 4) provide useful insights on the potential site/cell of origin of these aggressive FMCs. We found two separate lineages, both with precursor and terminally differentiated cells that had a different distribution pattern in the non-neoplastic glands. Terminally differentiated luminal (CK8_18+) and myoepithelial (VIM+/CALP+/aSMA+) cells were present within the lobules. The ductal system was characterized by basal intermediate progenitors (VIM+/CK5_6+/CK14+/CALP+/aSMA+) and luminal cells that diffusely co-expressed CK8_18 and VIM. The subgroup of “ductal-associated” tumors overlapped this dual (biphasic) component and had a less aggressive (grade I) HRs+ phenotype, suggesting a more stable ductal-differentiation.

Exclusively and consistently at the ductal-lobular junction of the non-neoplastic glands (possibly terminal end buds region) the luminal cells stained with CK14. In the more common, aggressive, predominantly triple-negative, “non-ductal associated” FMCs the biphasic nature was not present. A diffuse increase of CK14 and a moderate positivity to CK5_6 were observed.

As indicated by Figure 4, and similarly to what reported for HBCs [3,5], all these data suggest that these “non-ductal associated” FMCs arise at the ductal-lobular junction where potential stem/progenitor cells (CK5_6+) reside to expand the normal glandular lobules and are capable to give rise to CK8_18+/CK14+/VIM + clones responsible for the heterogeneity of these FMCs supporting the idea that tumor arise from stem cells [5,14].

Two hypotheses are instead consistent for the less aggressive “ductal-associated” FMTs. i) They might originate at the same site, but progressing along a more differentiated phenotype with no or minimal stem/progenitor content (CK5_6 negative). ii) Alternatively they might arise in a more proximal ductal region from intermediate progenitor cells (Figure 4).

There is very little data describing the co-expression of cytokeratins (CK8_18) and vimentin in non-tumoral
epithelium (i.e. human ciliary epithelium and bovine reproductive tract) [49,50]. Usually their co-expression has been associated with drug resistance, invasion and tumor metastasis [48]. In the feline gland the coexpression of cytokeratin and vimentin may indicate a non-terminally differentiated luminal component that is diffusely distributed in the ducts, corroborating the hypothesis that also vimentin positive HBCs (TNBCs) may originate from a precursor cell with bilineage differentiation potential and not from an EMT process [45]. This may also explain why a small subset of the TNBCs are less aggressive histological subtypes and/or show myoepithelial differentiation (i.e. metaplastic and adenoid cystic) [10]. Vimentin has never been described in the non-neoplastic luminal epithelium of the mammary gland of any species, however, it has been described in the so-called ‘cap cells’ of the mice and in the “side-population” of human breast containing the progenitor cell compartment, further
validating a potential role of early breast progenitor cells in the pathogenesis of vimentin-expressing breast cancers [45]. A species-specific distribution of these progenitors might explain why in cats mammary cancer is frequently an aggressive, triple-negative, vimentin-positive carcinoma.

Conclusions
Our study supports the hypothesis that FMCs are generally aggressive HRs negative cancers that manifest an heterogeneous phenotype characterized by basal cytokeratins and vimentin expression. They appear similar to the TNBCs, particularly to the claudin-low subclass and they might originate from progenitor/precursor cells at the ductal-lobular junction. A second subgroup of less common and less aggressive “dualt-associated” FMTs might instead originate from a hierarchically more advanced precursor or from a more distal ductal portion with less stem progenitors. These results indicate that a species-specific phenotype and distribution of cell lineages within the mammary gland might explain the development of species-specific tumor subtypes. The feline species might represent a good model to study a certain type of HBC, to better understand cancer pathogenesis, and to address novel targeted therapies.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
DC completed part of his PhD working on this project; VZ also participated to data collection, planning of experiments, and revision of results; DC and VZ drafted together the paper; RP performed part of the IHC analyses; BC and FF were involved for the molecular analyses; MB, van de Rijn M, Sweep FC, Taube S, Torlakovic EE, Valenkoten P, Viale G, Visscher D, Wheeler T, Williams RB, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010, 28:2784–2795.

Weigelt B, Reis-Filho JS. Histological and molecular types of breast cancer: is there a uniformly taxonomy? Nat Rev Clin Oncol 2009, 6:718–730. Review.

Reis-Filho JS. Spontaneous feline mammary intraepithelial lesions as a model for human estrogen receptor- and progesterone receptor-negative breast lesions. Vet Pathol 2010, 47:1–17.

Brenner S, Viale G, Visscher D, Wheeler T, Williams RB, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010, 28:2784–2795.

5. Malhotra GK, Zhao X, Band H, Band V: Histological, molecular, and functional subtypes of breast cancer. Cancer Biol Ther 2010, 10:955–960. Review.

6. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Berde S, Fitzgibbon PL, Francis G, Goldstein HS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Permutt J, Rhodes A, Saino H, Schwartz JW, Sinicrope FA, Sweep FC, Taube S, Torlakovic EE, Valenkoten P, Viale G, Visscher D, Wheeler T, Williams RB, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010, 28:2784–2795.

Received: 9 January 2014 Accepted: 8 August 2014
Published online: 25 September 2014

References
1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11–30.

2. Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61–70.

3. Prat A, Perou CM: Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011, 5:5–23.

4. Sarlak T, Perou CM, Tibshirani R, Aas T, Geiser S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lander ES, Børresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98:10869–10874.

5. Malhotra GK, Zhao X, Band H, Band V: Histological, molecular, and functional subtypes of breast cancer. Cancer Biol Ther 2010, 10:955–960. Review.

6. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Barde S, Fitzgibbon PL, Francis G, Goldstein HS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Permutt J, Rhodes A, Saino H, Schwartz JW, Sinicrope FA, Sweep FC, Taube S, Torlakovic EE, Valenkoten P, Viale G, Visscher D, Wheeler T, Williams RB, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010, 28:2784–2795.

7. Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, McShane L, Paik S, Penault-Llorca F, Prudkin L, Regan M, Salter J, Sotiriou C, Smith IE, Viale G, Zujewski JA, Hayes DF, International Ki-67 in Breast Cancer Working Group: Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 2011, 103:1656–1664.

8. Matos A, Baptista CS, Gänzer MR, Rutteman GR: Prognostic studies of canine and feline mammary tumours: the need for standardized procedures. Vet J 2012, 198:24–31.

9. Houk CR, Scott PB, Kluender A, Kluenders T, Kluender ME, Kluender J: The management and treatment of feline mammary neoplasia. J Feline Med Surg 2003, 5:189–194.
carcinoma: optimization of Immunohistochemistry (IHC) and In Situ Hybridization (ISH) Techniques. Microsc Microanal 2013, 30:1–7.

24. Zappulli V, De Cecco S, Tres D, Caliari D, Areus E, Castagnaro M. Immunohistochemical expression of E-cadherin and β-catenin in feline mammary tumours. J Comp Pathol 2012, 147:161–170.

25. Perkañel-Herdu C, Buednza AJ, Navarro JA, Ramirez GA, Wifranca M, Altmira J, Sanchez J. Reduced expression of E-cadherin and β-catenin and high expression of basal cytokeratins in feline mammary carcinomas with regional metastasis. Vet Pathol 2012, 49:979–987.

26. Martín De Las Mulas J, Reyinando C, Espinosa De Los Monteros A, Millán Y, Ordás J. Calponin expression and myoepithelial cell differentiation in canine, feline and human mammary simple carcinomas. Vet Comp Oncol 2004, 2:24–35.

27. Paoloni M, Khanna C. Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer 2008, 8:147–156.

28. Porrello A, Cardelli P, Spugnini EP. Oncology of companion animals as a model for humans. an overview of tumor histotypes. J Exp Clin Cancer Res 2006, 25:807–815. Review.

29. Rani G, Gadaleeta CD, Pathansu R, Zizzo N, Daidone MG, Hansson MG, Paradiso A, Ribatti D. A model of study for human cancer: spontaneous occurring tumors in dogs: biological features and translation for new cancerantigens therapies. Curr Rev Oncol Hematol 2013, 88:1–187–197.

30. Vargo-Gogola T, Rosen JM. Modelling breast cancer: one size does not fit all. Nat Rev Cancer 2007, 7653–672.

31. Zappulli V, Caliari D, Racitto R, Fero S, Castagnaro M, Goldschmidt M. Proposed classification of the feline ‘complex’ mammary tumours as ducal and intraductal papillary mammary tumours. Vet Pathol 2013, 50(6):1070–1077.

32. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer: I: the value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19:403–410.

33. Castagnaro M, Casalone C, Bozza A, De Maria R, Bolati B, Caramelli M. Tumour grading and the one-year post-surgical prognostic in feline mammary carcinomas. J Comp Pathol 1998, 119:263e275.

34. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO. K67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009, 101:36–75.

35. Goldhirsh A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ. Panel members. Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011, 22:1736–1747.

36. Hammond ME. ASCO-CAP guidelines for breast predictive factor testing: an update. Appl Immunohistochem Mol Morphol 2011, 19:49–500.

37. Wolff AC, Hammond ME, Schwartz IN, Hagerty KL, Allegra DJ, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A. Immunohistochemical staining of estrogen receptor, progesterone receptor, and HER-2/neu in breast carcinoma: correlation with clinical behavior and proposed guidelines for use in human breast cancer. J Clin Oncol 1991, 9:1927–1939.

38. Stehlin AG, Salleras LM, Langer A. Comparison of an immunohistochemical staining procedure for estrogen receptor and HER-2/neu in human breast carcinoma with a commercially available assay. Clin Cancer Res 1995, 1:197–203.

39. Trotti A, Sopel LM, Figg WD, Hainsworth JD, Blumenschein GR, Cloughesy TF, Paulson D, Hanson L, King K, Nathanson G. Validation of the HercepTest and routine C-erbB2 immunohistochemistry in breast cancer: any difference? J Clin Oncol 2000, 18:2649–2656.

40. Kim TJ, Lee A, Choi Y, Song BJ, Yim HW, Kang CS. Intermediate filament associated proteins. Adv Protein Chem 2005, 70:143–202.

41. Kirschning I, Packeisen J, Liebich C, Hungermann D, Wülfing P, Van Diest PJ, Brandt B, Boeckler W, Buerger H. The origin of vimentin expression in invasive breast cancer: epithelial-mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential? J Pathol 2005, 206:451–457.

42. Uskujusu RO, Kordek R, Plucieniak E, Bednarek AK, Piekarshi JH, Potemski P. Does vimentin help to delineate the so-called ‘basal type breast cancer’? J Clin Exp Oncol 2009, 28:118.

43. Yamashita N, Tokunaga E, Kitao H, Hiatsam Y, Taketani K, Akiyoshi S, Okada S, Aishima S, Morita M, Maehara Y. Vimentin as a poor prognostic factor for triple-negative breast cancer. J Cancer Res Clin Oncol 2013, 139:739–746.

44. Yer SV, Dange PP, Alam H, Savant SS, Ingle AD, Borges AM, Sihard NV, Dalal SN, Vaidya MM. Understanding the role of keratins 8 and 18 in neoplastic potential of breast cancer derived cell lines. PLoS One 2013, 8:e53532.

45. Kasper M, Roll M, Stosiek P, Karsten U. Patterns of cytotkeratin and vimentin expression in the human eye. Histochemistry 1988, 89:369–377.

46. Perez-Martinez C, Garcia-Fernandez RA, Escudero A, Ferreras MC, Garcia-Iglesias MJ. Expression of cytokeratins and vimentin in normal and neoplastic tissue from the bovine female reproductive tract. J Comp Pathol 2001, 124:70–78.

Cite this article as: Caliari et al. Triple-negative vimentin-positive heterogeneous feline mammary carcinomas as a potential comparative model for breast cancer. BMC Veterinary Research 2014 10:185.